Inflammatory bowel disease (IBD) is a chronic, recurrent gastrointestinal disorder with
elusive etiology. Interleukin-12 (IL-12) and IL-23 have emerged as key proinflammatory …

Background Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative
colitis, are chronic inflammatory conditions affecting the gastrointestinal tract. To achieve …

Background: Ustekinumab (UST) is an IL12/23 inhibitor utilized for altering inflammatory
responses in inflammatory bowel disease (IBD). Clinical trials and case reports suggested …

Introduction Ustekinumab, an interleukin-12 and interleukin-23 antagonist, is licensed for the
treatment of Crohn's disease (CD) and ulcerative colitis (UC) after the phase III trial …

As our comprehension of the pathogenic mechanisms of inflammatory bowel disease (IBD)
increases, the therapeutic armamentarium for its treatment can expand, and novel target …

Inflammatory bowel diseases including Crohn's disease (CD) and ulcerative colitis (UC) are
characterized by abdominal pain, diarrhea, blood in stools, weight loss, and fatigue. It …

Ustekinumab is a fully human IgG1 monoclonal antibody that has been approved for the
treatment of moderate to severe Crohn's disease, and more recently moderate to severe …

Introduction: Ulcerative colitis (UC) is a chronic relapsing disorder of the colonic tract.
Dysregulated innate and adaptive immune pathways contribute to intestinal inflammation in …

Introduction The aim of treatment in inflammatory bowel disease (IBD) is to control symptoms
and suppress gut inflammation with minimal systemic side effects. A large proportion of …

Ustekinumab (UST) is a human monoclonal antibody that binds the shared p40 protein
subunit of human interleukins (IL) 12 and 23. It is approved for both refractory Crohn's …